Trial Information - Phase II
A Phase 2, Single-Arm, Open-Label Study of Trilaciclib Administered Prior to Sacituzumab Govitecan-hziy in Patients with Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments, at Least One in the Metastatic Setting (G1T28-213)
Disease Specifics: (mTNBC)
Protocol ID: G1T28-213
Sponsor: G1 Therapeutics
Status: STAR TRIAL
Contact us regarding Clinical Trials at MOHRSCH@usoncology.com
or call us at
877-664-7724
